12th Mar 2021 07:00
Agreement with the UK Department of Health & Social Care to pilot Sensyne Health's MagnifEyeÔ technology for use with COVID-19 lateral flow diagnostic tests
Oxford, U.K. 12 March 2021: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the British Clinical AI technology company, today announces it has signed a £470,000 agreement with the Department of Health & Social Care to conduct the second stage of a pilot study of its MagnifEye technology for use with COVID-19 lateral flow diagnostic tests.
The agreement with the Department of Health & Social Care follows an announcement made by Sensyne on 09 February 2021 that it had signed an exclusive licence and development agreement with Excalibur Healthcare Services Limited to apply MagnifEye for use with lateral flow rapid diagnostic tests.
Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:
"We are delighted to be working with the Department of Health & Social Care and Excalibur and are happy to be able to contribute to the UK's COVID-19 testing programme by providing our MagnifEye technology for use with lateral flow diagnostic tests and look forward to the results of this pilot study."
-ENDS-
For more information please contact:
Sensyne Health (www.sensynehealth.com) | +44 (0) 330 058 1845 |
Lord (Paul) Drayson PhD FREng, Chief Executive Officer | |
Dr Richard Pye, Chief Financial Officer | |
Peel Hunt LLP (Nominated Adviser and Joint Broker) |
+ 44 (0) 20 7418 8900 |
Dr Christopher Golden | |
James Steel | |
Oliver Jackson | |
Liberum (Joint Broker) | + 44 (0) 20 3100 2000 |
Bidhi Bhoma | |
Euan Brown | |
Consilium Strategic Communications | +44 (0) 20 3709 5700 |
Mary-Jane Elliott | |
Sukaina Virji | |
Davide Salvi | |
About Sensyne Health www.sensynehealth.com.
Sensyne Health plc is a clinical AI company that works in partnership with the NHS to improve patient care and accelerate the discovery and development of new medicines. This work uses data provided by patients and collected by the NHS as part of their care and support. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).
About MagnifEye
The MagnifEye system ("the System") is Sensyne's proprietary software application available as both a smartphone app and a web application, that uses a cloud-based deep learning algorithm to automate the reading and analysis of different diagnostic tests including lateral flow tests. The System has been adapted to Excalibur's already high-performance lateral flow Antigen test. The System trains users to administer a lateral flow test, then interpret that test and provide a shareable digital certificate that validates the training of the user, the test result and resulting health status. It is anticipated that this will facilitate frequent testing, both for COVID-19 and a range of other conditions.
Related Shares:
SENS.L